| Document |
Document Title |
|
WO/2024/099391A1 |
Disclosed herein are a lipid-charged molecule conjugate, an inhalable lipid nanoparticle, a preparation method therefor, and use thereof. The lipid-charged molecule conjugate of the present invention comprises a lipid unit and a charged ...
|
|
WO/2024/098890A1 |
A pyridone compound and a preparation method therefor, a pharmaceutical composition and a use. The structure of the pyridone compound is as shown in formula (I), and the pyridone compound comprises an isomer, a pharmaceutically acceptabl...
|
|
WO/2024/064716A3 |
Isolated T cell receptors (TCRs) that specifically recognize a peptide derived from an HPV E6 or E7 protein are described. The TCRs include an alpha chain variable region and a beta chain variable region having the complementarity determ...
|
|
WO/2024/100549A1 |
The present invention relates to compounds for use for treating and/or preventing tumors by virtue of the ability to reprogram tumor-associated macrophages M2 (TAM-M2) to tumor-associated macrophages M1 (TAM-M1).
|
|
WO/2024/102177A1 |
Disclosed herein are methods of treating brain cancer in a subject, such as glioblastoma, comprising administering inhibitors of synaptic signaling to the subject.
|
|
WO/2024/100203A1 |
Methods of cancer treatment comprise administration of a modified natural killer (NK) cell in combination with an immunomodulatory drug. Also described are compositions comprising a combination of a modified NK cell and an immunomodulato...
|
|
WO/2024/102342A1 |
The present invention relates to a process of removing free-unlabeled radionuclides from a radiopharmaceutical prior to administering the radiopharmaceutical to the patient using size-exclusion or ion-exchange mechanisms.
|
|
WO/2024/100212A1 |
The application relates to the crystalline Form 1S of Asciminib hydrochloride and processes for the preparation thereof. Also described are solvates of Asciminib with 2-butanol, isobutanol, tert- butanol, 2-methyl tetra hydrofuran and cy...
|
|
WO/2024/102078A1 |
This invention provides compounds according to formula (I): wherein A and Za are as defined in the specification. The compounds of formula (I) find use as heterobifunctional linkers. The present invention also provides compounds of formu...
|
|
WO/2024/102706A1 |
Provided herein are methods of treating, preventing, managing, and/or ameliorating androgen receptor mediated diseases with a combination of 3-((3- aminophenyl)amino)piperidine-2, 6-dione compounds and a second agent.
|
|
WO/2024/099336A1 |
The disclosure relates to thiadiazolyl derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
|
|
WO/2024/099226A1 |
The present invention relates to a biphenyl heteroaryl-containing dihydropteridinone derivative represented by general formula Ⅰ, and an optical isomer, pharmaceutically acceptable salt, solvate or prodrug thereof, a preparation method...
|
|
WO/2024/102969A1 |
The present disclosure provides compositions and methods of modulating the response of a subject to an anti-cancer treatment, comprising fecal-derived extracellular vesicles, filtrates or compositions comprising the same, which can be ad...
|
|
WO/2024/099975A1 |
The invention relates to nanoparticles for Cas protein/gRNA ribonucleoprotein (RNP) complex, siRNA or PMO delivery comprising one or more Cas protein/gRNA RNP complex(es), siRNA(s) or PMO(s) as cargo; and a carrier comprising a sequence-...
|
|
WO/2024/101386A1 |
The present inventors found a cyclic compound that selectively inhibits KRAS. The present inventors also found that the cyclic compound interacts with a KRAS-specific amino acid residue.
|
|
WO/2024/098894A1 |
Provided are a tumor-targeted imaging nano assembly, a preparation method therefor, and use thereof. The nano assembly comprises an active targeting unit, an imaging signal unit, and metal ions. The active targeting unit is coordinated w...
|
|
WO/2024/099404A1 |
The present application relates to a nitrogen-containing spirocyclic compound, a pharmaceutical composition and a use thereof. The nitrogen-containing spirocyclic compound has the structural formula represented by formula (I). The compou...
|
|
WO/2024/076750A3 |
The present disclosure relates to pharmaceutical compositions comprising engineered macrophages and methods of use thereof. In some aspects, the present disclosure relates to engineered macrophages derived from pluripotent stem cells. In...
|
|
WO/2024/100095A1 |
The present invention pertains generally to the field of diagnostic and therapeutic compounds. More specifically the present invention pertains to certain radiolabelled compounds, their precursors, and the respective uses. The radiolabel...
|
|
WO/2024/100656A1 |
The present invention provides delivery system compositions comprising self- assembling lipid nanoparticles for targeted delivery of therapeutic or diagnostic agents to target cells. The particles are non-covalently attached to a lipidat...
|
|
WO/2024/099520A1 |
The invention relates to 4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. Here, a compound of general formula (I) is provided, where X is selected from the group consisting of a group of general formula (G1), a group of general fo...
|
|
WO/2024/101764A1 |
The present invention relates to: an isoindolinone derivative compound having a glutarimide mother nucleus in which quinoline is substituted; and application thereof, and, more specifically, to an isoindolinone derivative compound having...
|
|
WO/2024/059677A3 |
Provided herein are PD-1 agonist antibodies which bind PD-1. The PD-1 agonist antibodies of the disclosure are useful for the treatment of autoimmune and inflammatory diseases through the promotion of PD-1 signaling. Also provided herein...
|
|
WO/2024/102985A1 |
The present disclosure is related to spliceosome perturbations. Provided herein are methods of inducing an immune response to a cancer cell. Also provided are methods to treat a subject in need thereof e.g., a subject suffering from cancer.
|
|
WO/2024/099435A1 |
The present invention provides a compound represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. As a TEAD inhibitor, the compound can significantly inhibi...
|
|
WO/2024/102927A1 |
The disclosure provides compounds, in part, compounds of Formula I, Formula II or Formula III and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical composit...
|
|
WO/2024/102282A1 |
Provided herein are methods of reducing immune checkpoint therapy resistance, increasing immune checkpoint therapy sensitivity and/or increasing anti-tumor activity in subjects with cancer, methods of treating non-small cell lung cancer ...
|
|
WO/2024/100250A1 |
In a first aspect, the invention relates to a combination of at least one menin inhibitor with at least one immunoproteasome inhibitor for use as medicament, preferably for use in the treatment of leukemia. A second aspect of the inventi...
|
|
WO/2024/102467A1 |
Compositions, systems, and kits are disclosed that comprise at least one immune checkpoint inhibitor and at least one immune cell type for adoptive cell therapy, wherein the at least one immune cell type has been fucosylated ex vivo (fuc...
|
|
WO/2024/102523A1 |
The present disclosure relates to novel glycosynthase enzymes for antibody-drug conjugates (ADCs) engineering. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the ...
|
|
WO/2024/102332A1 |
The present application relates to vaccine compositions comprising one or more neoantigen(s), wherein the one or more neoantigen(s) is associated with KRAS, a pharmaceutically acceptable carrier, and optionally an adjuvant and/or T-helpe...
|
|
WO/2024/098142A1 |
Monovalent antibodies such as single-domain antibodies (sdAbs) that are specific for galectin- 13/16 or galectin-9 are described. These monovalent antibodies are able to interfere with the activity of galectin-13/16 or galectin-9, and th...
|
|
WO/2024/099440A1 |
A fused ring compound, a use thereof, and a pharmaceutical composition containing same. The compound has a strong inhibitory effect on BRM ATPase, and has a good application prospect in BRG1 gene mutation tumors.
|
|
WO/2024/073622A3 |
Provided herein are radiopharmaceutical conjugate compositions targeting EphA2 and uses thereof. In one aspect, provided herein are conjugates that comprise a peptide with avidity to EphA2 and a metal chelator configured to bind with a r...
|
|
WO/2024/100093A1 |
The present invention relates to compounds that can specifically activate TLR7. The compounds of the invention are useful because they can stimulate innate immunity. The compounds of the invention can be used in the treatment of conditio...
|
|
WO/2024/102759A1 |
Aspects herein relate to methods, compositions, and systems directed to the discovery that TSG-6 secretion by cancer-associated fibroblasts (CAFs) in a tumor, in some instances, leads to a poor response to immune checkpoint therapies in ...
|
|
WO/2024/102704A2 |
Provided are methods and compositions for use in cancer immunotherapies. In various embodiments, the compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iP...
|
|
WO/2024/098980A1 |
Provided are CD112R-binding proteins, particularly anti-CD112R antibodies and antigen-binding fragments thereof. Further provided are compositions comprising the CD112R-binding proteins, nucleic acid molecule encoding the antigen-binding...
|
|
WO/2024/101965A1 |
The present disclosure pertains to a pharmaceutical combination for treating and/or preventing cancer and a method and use thereof. Specifically, the present disclosure involves a method for inhibiting tumor growth by combining a substan...
|
|
WO/2024/102477A1 |
The invention relates to a crystalline form of the compound represented by Structural Formula 1, and pharmaceutical compositions comprising the crystalline form of the compound represented by Structural Formula 1 described herein. The cr...
|
|
WO/2024/102956A1 |
Conjugates comprising a fibroblast activation protein alpha (FAPα)-targeted ligand, a bifunctional or trifunctional linker, and an imaging or therapeutic agent; compositions comprising the conjugates; and methods of use in the imaging a...
|
|
WO/2024/101961A1 |
The present invention relates to cells genetically modified to express a peptide capable of inhibiting the transforming growth factor beta (TGF-β) signaling pathway or a fragment of the peptide.
|
|
WO/2024/100663A1 |
Pharmaceutical compositions comprising anti-CEACAMl mAbs, and their use in inhibition of NET-mediated activities, and in prevention and treatment of pathologies associated with these activities are provided and exemplified with the mAb C...
|
|
WO/2024/100452A2 |
The disclosure relates to a compound represented by Formula 1, or a pharmaceutically acceptable salt thereof, as a stimulator of interferon genes (STING) agonist, pharmaceutical compositions comprising the same, and related methods of an...
|
|
WO/2024/099242A1 |
Provided are a deuterated aminopyridine derivative as represented by formula I, an optical isomer or mixture thereof, a polymorph thereof, a salt thereof, or a hydrate or solvate thereof; further provided is a pharmaceutical composition ...
|
|
WO/2024/099438A1 |
Disclosed in the present invention are compounds as SUMO activating enzyme inhibitors. Particularly, the present invention relates to compounds as represented by general formula (1) and general formula (2) and preparation methods therefo...
|
|
WO/2024/100548A1 |
The present invention relates to the medical use of a compound in the treatment of tumor metastases.
|
|
WO/2024/098193A1 |
Provided is a use of mitochondrial fusion protein 2 (MFN2), an MFN2 variant capable of interacting with SERCA2, or an MFN2 expression promoter in maintaining and/or promoting tumor killing and/or viability of a CD8 T cell. Also provided ...
|
|
WO/2024/099517A1 |
The invention relates to salts of 4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. A compound of general formula (IA) or (IB) is provided, where A represents -C=C- and n is 0 or 1; R1 is selected from among the group consisting of...
|
|
WO/2024/076499A3 |
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the s...
|
